Exondys 51 (Eteplirsen)

Exondys 51 (eteplirsen) is an antisense oligonucleotide used for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Note: This medicine, Exondys 51, was approved early because it showed that it could increase a protein known as dystrophin in the muscles of some patients. However, this approval will continue only if future studies prove that the therapeutic drug also helps patients feel better or improve their health.

Recommended Dosage:
The recommended dosage of Exondys 51 is 30 mg per/kg administered once weekly as a 35 to 60 minute intravenous (IV) infusion via an in-line 0.2 micron filter.
In case any scheduled dose is missed/skipped, it may be administered as quickly as possible after the scheduled time.

• Treatment with Eteplirsen 100 mg/2 mL injection may cause hypersensitivity reactions such as fever, rash, or difficulty breathing. If any signs and symptoms of allergy arise after administration, stop use and get immediate medical help. Monitor patients watchfully during and after infusion for any signs of allergic response.
• There are not sufficient studies on the use of Eteplirsen injection during pregnancy. Use only if clearly needed and if the potential benefit justifies the potential risks to the unborn baby. Pregnant women should consult a healthcare professional (HCP) before starting treatment with Eteplirsen.
• It is not known whether this medicine is excreted in human breast milk. Caution is required when administering it to breastfeeding mothers. A healthcare provider (HCP) should evaluate the benefits of treatment against any potential risk to the nursing child before starting treatment.
• This medicine is specifically approved for use in pediatric patients with Duchenne muscular dystrophy (DMD). Safety and efficacy have been established in children. However, regular monitoring is important to assess the medicine’s effect and ensure there are no adverse developmental impacts.
• There is limited clinical experience with Eteplirsen 500 mg/10 mL injection in patients aged 65 and older. No overall differences in safety or effectiveness have been observed. However, treat elderly patients cautiously. Consider age-related conditions and potential coexisting health concerns.
• No specific dosing adjustment is required for those with renal impairment. However, since this medicine is cleared by the kidneys, monitor renal function throughout treatment. Consult with a nephrologist before starting therapy in those with pre-existing kidney complications.

What documents are required to import EXONDYS 51 to India?

 Is EXONDYS 51 available in India?

Indian Pharma Network can source EXONDYS 51 (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Exondys 51®?

Eteplirsen is the Generic Name for the trade name drug Exondys 51®.

What is the Manufacturer’s Name of Exondys 51®?

Exondys 51® is manufactured by Sarepta Therapeutics.

Is Exondys 51® approved by the FDA?

Yes, Exondys 51® is approved by the FDA. Date of first approval: September 19, 2016.

What is the dosage and form of Exondys 51® supplied?

Exondys 51 is supplied in Injection 100 mg/2 mL (50 mg/mL) and 500 mg/10 mL (50 mg/mL) in a single-dose vial for intravenous (IV) use.

What are the most common side effects of Exondys 51® injections? 

The most common side effects of Exondys 51® injection are balance disorder and vomiting.

How much does Exondys 51® injection cost in India?

Prices of Exondys 51 injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Exondys 51 injection cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Exondys 51® injections be available in SAARC countries? 

Apart from Gulf countries, Exondys 51® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Exondys 51® injections in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Exondys 51® injections online in India?

Yes, one can buy Exondys 51 injection online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Exondys 51® injections through legal channels. 

What are the storage conditions of Exondys 51® injections?

Store the vials of Exondys 51® at 2-8°C (36-46°F). Do not freeze. Protect from light and store this drug in the original carton until ready for use.